Expression and significance of RRBP1 in esophageal carcinoma
Authors Wang L, Wang M, Zhang M, Li X, Zhu Z, Wang H
Received 24 November 2017
Accepted for publication 18 January 2018
Published 17 May 2018 Volume 2018:10 Pages 1243—1249
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Professor Nakshatri
Liang Wang,1 Ming Wang,2 Mingyun Zhang,1 Xingde Li,1 Zhongcheng Zhu,1 Haiyan Wang2
1Department of Endoscopic Professional, Cangzhou Central Hospital, Cangzhou, China; 2Department of Radiation Therapy, Cangzhou Central Hospital, Cangzhou, China
Objective: This study was to investigate the expression and clinical significance of RRBP1 in esophageal carcinoma.
Materials and methods: RRBP1 expression was detected in 120 esophageal carcinoma and matched adjacent normal tissues, and the relationship of RRBP1 with clinicopathological characteristics and prognosis was analyzed.
Results: RRBP1 was highly expressed in esophageal carcinoma tissues compared with matched adjacent normal tissues (P<0.05). Moreover, RRBP1 expression was associated with T stage, lymph node metastasis, and TNM stage in esophageal carcinoma (P<0.05). Survival analysis revealed that RRBP1, T stage, lymph node metastasis, and TNM stage were significantly associated with patients’ prognosis.
Conclusion: RRBP1 is highly expressed in esophageal carcinoma and can serve as a potential biomarker to predict patients’ prognosis.
Keywords: RRBP1, prognosis, esophageal carcinoma, survival analysis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]